stockrow
Friday 6 November 2026
Export PTGX’s income statement to Excel — free account
Protagonist Therapeutics, Inc.
PTGX Healthcare Biotechnology
Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.
- Revenue
- +3,749.2%
- EPS
- +549.1%
- Free cash flow
- +839.7%
Quarter to June 2026, against a year earlier
131.78
3.48
−2.57%
Follow PTGX
Alert me
Protagonist Therapeutics, Inc. (PTGX) Total debt
Protagonist Therapeutics, Inc.'s total debt at the end of fiscal 2022 was $1.1M, down 68.8% from $3.7M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $1.8M. Protagonist Therapeutics, Inc. ranks 346th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $1.1M | (68.81%) |
| FY2021 | $3.7M | (18.71%) |
| FY2020 | $4.5M | (54.05%) |
| FY2019 | $9.8M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $1.8M | (26.29%) |
| Jun 2023 | $2.4M | 429.44% |
| Mar 2023 | $462.0K | (59.51%) |
| Dec 2022 | $1.1M | (36.75%) |
| 15 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| IBRX ImmunityBio, Inc. compare | $774.4M |
| TGTX TG Therapeutics, Inc. compare | $745.4M |
| CAI Caris Life Sciences,�Inc. compare | $393.3M |
| SYRE Spyre Therapeutics, Inc. compare | $387.1M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | $341.3M |
| CYTK Cytokinetics, Incorporated compare | $174.4M |
| TWST Twist Bioscience Corporation compare | $15.0M |
| KRYS Krystal Biotech, Inc. compare | $8.3M |
| PTGX Protagonist Therapeutics, Inc. | $1.8M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on PTGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement